HitGen Hits China Drug Discovery Jackpot With MNC Tie-ups

Wei Chen, head of R&D for Chengdu-based venture HitGen, talks to Scrip’s Brian Yang on how the Chinese startup is partnering with multinationals and is aiming to speed up new drug development in China through its own platform and a novel HDAC inhibitor for liver cancer.